

## Literatura ACTA MEDICINAE 9/2018 Revmatologie

- 2 **Biosimilární léky v revmatologii v roce 2018**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Biologická léčba v graviditě**  
MUDr. Dana Tegzová Revmatologický ústav, Praha
- 2 **Komentář ke studii FUTURE: Inhibice interleukinu 17A je účinnou možností léčby psoriatické artritidy**  
doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie, LF a FN Hradec Králové
- 2 **Secukinumab v dlouhodobé léčbě axiálních spondyloartritid**  
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň, Ústav farmakologie 2. LF UK, Praha
- 3 **Gonokoková artritida – možný diferenciálnědiagnostický problém – kazuistika**  
MUDr. Tereza Barochová Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 3 **Vliv adalimumabu na kvalitu života, únavu a práce schopnost pacientů s axiální spondyloartritidou**  
doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 3 **Některé neznámé artropatie v diferenciální diagnostice juvenilní artritidy**  
prof. MUDr. Pavla Doležalová, CSc. Centrum dětské revmatologie a autoinflatorních onemocnění, Klinika dětského a dorostového lékařství VFN a 1. LF UK, Praha
- 3 **Inhibitory interleukinu 6 v léčbě revmatoidní artritidy**  
MUDr. Heřman Mann Klinika revmatologie 1. LF UK a Revmatologický ústav, Praha
- 4 **Současné postavení inhibitorů Janus kináz v terapii revmatoidní artritidy**  
MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha
- 4 **Dlouhodobé klinické zkušenosti s tofacitinibem a jeho zařazení do léčby revmatoidní artritidy**  
MUDr. Zdeněk Fojtík, Ph.D. Revmatologická ambulance, Interní a hematologická klinika FN a LF MU, Brno
- 5 **Nový inhibitor interleukinu 6 sarilumab v terapii revmatoidní artritidy**  
MUDr. Hana Ciferská, Ph.D. | MUDr. Kateřina Zegzulková Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 5 **Inhibitory Janus kináz v léčbě revmatoidní artritidy – současné možnosti a poznatky**  
doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie LF UK a FN Hradec Králové
- 5 **Injekční roztok metotrexátu v předplněné injekční stříkačce – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 **Leflunomid v léčbě revmatoidní artritidy**  
MUDr. Martin Klein, Ph.D. Revmatologický ústav, Praha
- 6 **Injekční versus perorální forma nízkodávkovaného metotrexátu**  
doc. MUDr. Karel Urbánek, Ph.D. Ústav farmakologie LF UP a FN, Olomouc
- 6 **Léčba osteoartrózy v praxi**  
MUDr. Marta Olejárová, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 6 **Glukosamin sulfát v terapii osteoartrózy**  
MUDr. Monika Gregová, Ph.D. Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha

# Biosimilární léky v revmatologii v roce 2018

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 **Committee for Medicinal Products for Human Use: Guideline on similar biological medicinal products.** 2014. Dostupné z: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2014/10/WC500176768.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf), vyhledáno 20. 11. 2016.
- 2 **Dörner, T. – Strand, V. – Comes, P., et al.**: The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis*, 2016, 75, s. 974–982.
- 3 **Park, W. – Yoo, D. H. – Jaworski, J., et al.**: Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther*, 2016, 18, s. 25.
- 4 **Emery, P. – Vencovský, J. – Sylwestrzak, A., et al.**: A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*, 2017, 76, s. 51–57.
- 5 **Danese, S. – Gomollon, F.**, Governing Board and Operational Board of ECCO: ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). *J Crohns Colitis*, 2013, 7, s. 586–589.
- 6 **Yoo, D. H. – Prodanovic, N. – Jaworski, J., et al.**: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis*, 2017, 76, s. 355–363.
- 7 **Moots, R. – Azevedo, V. – Coindreau, J., et al.**: Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. *Curr Rheumatol Rep*, 2017, 19, s. 37, DOI: 10.1007/s11926-017-0658-4.
- 8 **Jorgensen, K. K. – Olsen, I. C. – Goll, G. L., et al.**: Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet*, 2017, 389, s. 2304–3216.
- 9 **Cohen, S. – Genovese, M. S. – Choy, E. – Perez-Ruiz, F. – Matsumoto, A. – Pavelka, K. – Pablos, J. L., et al.**: Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. *Ann Rheum Dis*, 2017, 76, s. 1679–1687.
- 10 **Smolen, J. S. – Choe, J.-Y. – Prodanovic, N., et al.**: Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. *Rheumatology*, 2017, 56, s. 1771–1779.
- 11 **Emery, P. – Vencovský, J. – Sylwestrzak, A., et al.**: 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. *Rheumatology*, 2017, 56, s. 2093–2101.
- 12 **Kay, J. – Schoels, M. – Dörner, T., et al.**: Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. *Ann Rheum Dis*, 2017, 0, s. 1–10, doi:10.1136/annrheumdis-2017-211937.
- 13 **The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use**, 2017, [www.ich.org](http://www.ich.org), vyhledáno 28. 1. 2017.
- 14 **Yoo, D. H. – Hrycaj, P. – Miranda, P., et al.**: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis*, 2013, 72, s. 1613–1620.
- 15 **Health Canada. Regulatory decision summary INFLECTRA**, 2016, dostupné z: <http://www.hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds-sdr-inflectra-184564-eng.php>, vyhledáno 29. 9. 2016.

## Biologická léčba v graviditě

MUDr. Dana Tegzová Revmatologický ústav, Praha

- 1 **Ostensen, M.**: The use of biologics in pregnant patients with rheumatic disease. *Exp Rev Clin Pharmacol*, 2017, 10, s. 661–669.
- 2 **Forger, F. – Vikliger, P. M.**: Treatment of rheumatoid arthritis during pregnancy: present and future. *Exp Rev Clin Immunology*, 2016, 12, s. 937–944.
- 3 **Clowse, M. U. B. – Scehuerle, A. E. – Chambers, C., et al.**: Pregnancy outcomes after exposure to certolizumab pegol: Updated results from Pharmacovigilance safety database. V tisku.
- 4 **Flint, J. – Panchal, S. – Hurrell, A., et al.**: BSR an BHRP guideline on prescribing drugs in pregnancy and breast feeding – part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. *Rheumatology*, 2016, 55, s. 1693–1697.
- 5 **Ostensen, M. – Andreoli, L. – Brucato, A., et al.**: State of the art: reproduction and pregnancy in rheumatic diseases. *Autoimmun Rev*, 2015, 14, s. 376–386.
- 6 **Levy, A. R. – De Jesús, G. R. – De Jesús, N. R., et al.**: Critical review of current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. *Autoimmun Rev*, 2016, 15, s. 955–963.
- 7 **Gotestam Skorpen, C., et al.**: The EULAR point to consider for use of antirheumatic drugs before pregnancy and during pregnancy and lactation. *Ann Rheum Dis*, 2016, 0, s. 1–16.
- 8 **Ostensen, M. – Forger, F.**: How safe are anti-rheumatic drugs during pregnancy? *Curr Opin Pharmacol*, 2013, 13, s. 470–475.
- 9 **Koh, J. H. – Ko, H. S. – Kwok, S. K. N., et al.**: Hydroxychloroquine and pregnancy on lupus flares in Korean patients with SLE. *Lupus*, 2015, 24, s. 210–217.
- 10 **Weber-Schoendorfer, C. – Chambers, C. – Wacker, E., et al.**: Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. *Reprod Toxicol*, 2014, 66, s. 1101–1110.
- 11 **Ostensen, M. – Khamashta, M. – Lockshin, M., et al.**: Anti-inflammatory, immunosuppressive drugs, reproduction. *Arthritis Res Ther*, 2006, 8, s. 209.
- 12 **Clowse, M. E. – Magder, L. – Witter, F., et al.**: Hydroxychloroquine in lupus pregnancy. *Arthritis Rheum*, 2006, 54, s. 3640–3647.
- 13 **Norgard, B. – Pedersen, L. – Christensen, L. A., et al.**: Therapeutic drug use in women with Crohns disease and birth outcomes: a danish nation wide cohort study. *Am J Gastroenterol*, 2007, 102, s. 1406–1413.
- 14 **Ghogomu, E. A. – Maxwell, L. J. – Buchbinder, R., et al.**: Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses. *J Rheumatol*, 2014, 41, s. 194–205.
- 15 **Izmirlir, P. M. – Costedoat-Chalumeau, N. – Pisconi, C. N., et al.**: Maternal use of hydroxychloroquine associated with reduced risk of recurrent anti SSA/Ro-antibody-associated cardiac manifestation on neonatal lupus. *Circulation*, 2012, 126, s. 76–82.
- 16 **Van Gelder, M. M. – Roeleveld, N. – Nordeng, H.**: Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. *PLoS ONE*, 2011, 6, s. e22174.
- 17 **Daniel, S. – Matok, I. – Gorodischer, R., et al.**: Major malformations following exposure to nonsteroidal anti-inflammatory drugs during the first trimester of pregnancy. *J Rheumatol*, 2012, 39, s. 2163–2169.
- 18 **Hoeltzenbein, M., et al.**: Tocilizumab use in pregnancy: Analysis of global safety database including data from clinical trials and postmarketing data. *Semin Arthritis Rheum*, 2016, s. 238–245.

## Komentář ke studii FUTURE: Inhibice interleukinu 17A je účinnou možností léčby psoriatické artritidy

doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie, LF a FN Hradec Králové

- 1 **Mease, P., et al.**: Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double blind, phase III FUTURE 5 study. *Ann Rheum Dis*, 2018, 77, s. 890–897.
- 2 **Raychaudhuri, S. P. – Raychaudhuri, S. K.**: Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. *Arthritis Res Ther*, 2017, 19, s. 51–60, doi: 10.1186/s13075-017-1249-1245.
- 3 **Koenders, M. I. – van den Berg, W. B.**: Secukinumab for rheumatology: development and its potential place in therapy. *Drug Des Devel Ther*, 2016, 10, s. 2069–2068, doi: 10.2147/DDDT.S105263.
- 4 **Chen, K. – Kolls, J. K.**: Interleukin-17A (IL17A). *Gene*, 2017, 614, s. 8–14, doi: 10.1016/j.gene.2017.01.016, Epub 22. 1. 2017.
- 5 **Mease, P. J. – Mc Innes, I. B. – Kirkham, B., et al.**: Secukinumab inhibition of interleukin 17-A in patients with psoriatic arthritis. *N Engl J Med*, 2015, 373, s. 1329–1339, doi: 10.1056/NEJMoa1412679.
- 6 **McInnes, I. B. – Mease, P. B. – Kirkham, B., et al.**: Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015, 386, s. 1137–1146, doi: 10.1016/S0140-6736(15)61134-5.
- 7 **Nash, P. – Mease, P. J. – McInnes, I. B., et al.**: Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). *Arthritis Res Ther*, 2018, 20, s. 47–58, doi: 10.1186/s13075-018-1551-x.
- 8 **Mease, P. – van der Heijde, D. – Landewé, R., et al.**: Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis*, 2018, 77, s. 890–897, doi:10.1136/annrheumdis-2017-212687.

## Secukinumab v dlouhodobé léčbě axiálních spondyloartritid

MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN Plzeň, Ústav farmakologie 2. LF UK, Praha

- 1 **Šenolt, L.**: Secukinumab v léčbě ankylozující spondylitidy. *Farmakoterapie*, 2016, 12, s. 363–368.
- 2 **Pavelka, K.**: Čtyřletá data o účinnosti a bezpečnosti secukinumabu v léčbě ankylozující spondylitidy. *Remedia*, 2018, 1, s. 35–41.
- 3 **Baeten, D. – Sieper, J. – Braun, J., et al.**; MEASURE 1 Study Group; MEASURE 2 Study Group: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. *N Engl J Med*, 2015, 373, s. 2534–2548.
- 4 **Baeten, D. – Braun, J. – Sieper, J., et al.**: Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 2-year efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled trial. Presented at: ACR/ARHP Annual Meeting, San Francisco, USA; 10. 11. 2015, *Arthritis Rheumatol*, 2014, 66, suppl., s. S360.
- 5 **Baraliakos, X. – Braun, J. – Sieper, J., et al.**: Secukinumab reduces sacroiliac joint and spinal inflammation in patients with ankylosing spondylitis: MRI data from a phase 3 randomized, double-blind, placebo-controlled study (MEASURE 1). Poster presentation at: European League Against Rheumatism (EULAR); Řím, Itálie; 11. 9. 2015, *Ann Rheum Dis*, 2015, 74, suppl. 2, s. 281.
- 6 **Braun, J. – Baraliakos, X. – Deodhar, A., et al.**: Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. *Arthritis Rheumatol*, 2017, 69, suppl. 10, abstrakt 3L.
- 7 **Deodhar, A. – Baraliakos, X. – Marzo-Ortega, H., et al.**: Secukinumab demonstrates consistent safety over long-term exposure (up to 4 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials. ACR 2017, abstrakt 1529.

# Gonokoková artritida – možný diferenciálnědiagnostický problém – kazuistika

MUDr. Tereza Barochová Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- Mathews, C. J., et al.: Bacterial septic arthritis in adults. *Lancet*, 2010, 375, s. 846–855.
- Belkacem, A. – Caumes, E. – Ouanich, J., et al.: Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009–2011. *Sex Transm Infect*, 2013, 89, s. 613–615.
- O'Brien, J. P. – Goldenberg, D. L. – Rice, P. A.: Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanism. *Medicine (Baltimore)*, 1983, 62, s. 395–406.
- Phupong, V. – Sittisomwong, T. – Wisawasukmongchol, W.: Disseminated gonococcal infection during pregnancy. *Arch Gynecol Obstet*, 2005, 273, s. 185.
- Petersen, B. H. – Lee, T. J. – Snyderman, R., et al.: Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7 or C8 deficiency. *Ann Intern Med*, 1979, 90, s. 917.
- Rice, P. A.: Gonococcal arthritis (disseminated gonococcal infection). *Infect Dis Clin North Am*, 2005, 19, s. 853–861.
- Bunker, D. – Kerr, L. D.: Acute myopericarditis likely secondary to disseminated gonococcal infection. *Case Rep Infect Dis*, 2015, 385126.
- Liebling, M. R. – Arkfeld, D. G., et al.: Identification of Neisseria gonorrhoeae in synovial fluid using the polymerase chain reaction. *Arthritis Rheum*, 37, 1994, s. 702–709.
- Workowski, K. A. – Bolan, G. A.: Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep*, 2015, 64, s. 1–137.

# Vliv adalimumabu na kvalitu života, únavu a práce schopnost pacientů s axiální spondyloartritidou

doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- Boonen, A. – Chorus, A. – Miedema, H., et al.: Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. *Ann Rheum Dis*, 2001, 60, s. 1033–1039.
- Martindale, J. – Shukla, R. – Goodacre, J.: The impact of ankylosing spondylitis/axial spondyloarthritis on work productivity. *Best Pract Res Clin Rheumatol*, 2015, 29, s. 512–523.
- Ware, J. E. Jr. – Sherbourne, C. D.: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*, 1992, 30, s. 473–483.
- McHorney, C. A. – Ware, J. E. Jr. – Raczek, A. E.: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*, 1993, 31, s. 247–263.
- Reilly, M. C. – Zbrozek, A. S. – Dukes, E. M.: The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*, 1993, 4, s. 353–365.
- Reilly, M. C. – Gooch, K. L. – Wong, R. L., et al.: Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire in ankylosing spondylitis. *Rheumatology (Oxford)*, 2010, 49, s. 812–819.
- van der Heijde, D. – Kivitz, A. – Schiff, M. H., et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
- Maksymowych, W. P. – Gooch, K. L. – Wong, R. L., et al.: Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. *J Rheumatol*, 2010, 37, s. 385–392.
- Rudwaleit, M. – Gooch, K. – Michel, B., et al.: Adalimumab improves sleep and sleep quality in patients with active ankylosing spondylitis. *J Rheumatol*, 2011, 38, s. 79–86.
- van der Heijde, D. – Joshi, A. – Pangan, A. L., et al.: ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. *Rheumatology (Oxford)*, 2016, 55, s. 80–88.
- van der Burg, L. R. – Ter Wee, M. M. – Boonen, A.: Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review. *Ann Rheum Dis*, 2012, 71, s. 1924–1933.
- Sobotík, Z.: Zkušenosti s použitím předběžné české verze amerického dotazníku o zdraví (SF36). *Zdravotnictví v ČR*, 1998, 1–2, s. 50–54.

# Některé nezářetlivé artropatie v diferenciální diagnostice juvenilní artritidy

prof. MUDr. Pavla Doležalová, CSc. Centrum dětské revmatologie a autoinflatorních onemocnění, Klinika dětského a dorostového lékařství VFN a 1. LF UK, Praha

- Goodman, J. E. – McGrath, P. J.: The epidemiology of pain in children and adolescents: A review. *Pain*, 1991, 46, s. 247–264.
- Kunnamo, I. – Kallio, P. – Pelkonen, P.: Incidence of arthritis in urban Finnish children. A prospective study. *Arthritis Rheum*, 1986, 29, s. 1232–1238.
- Denardo, B. A. – Tucker, L. B. – Miller, L. C., et al.: Demography of regional pediatric rheumatology patient population. *J Rheumatol*, 1994, 21, s. 1553–1561.
- Foster, H. E. – Jandial, S.: pGALS – paediatric Gait Arms Legs and Spine: a simple examination of the musculoskeletal system. *Pediatric Rheumatology*, 2013, 11, s. 44.
- Beighton, P. – Solomon, L. – Soskolne, C.: Articular mobility in an African population. *Ann Rheum Dis*, 1973, 32, s. 413–418.
- Murray, K. J. – Woo, P.: Benign joint hypermobility in childhood. *Rheumatology*, 2001, 40, s. 489–491.
- Armon, K.: Musculoskeletal pain and hypermobility in children and young people: is it benign joint hypermobility syndrome? *Arch Dis Child*, 2015, 100, s. 2–3.
- LeBlanc, C. – Houghton, K.: Noninflammatory musculoskeletal pain. In: *Textbook of pediatric rheumatology*, 2016, s. 663–680.
- Beighton, P. – De Paeppe, A. – Steinmann, B., et al.: Ehlers Danlos syndrome: revised nosology, Villefranche 1997. Ehlers Danlos National Foundation (USA) and Ehlers Danlos Support Group (UK). *Am J Med Gen*, 1998, 77, s. 31–37.
- Mueller, G. C. – Stark, V. – Steiner, K., et al.: The Kid-Short Marfan Score (Kid-SMS) – an easy executable risk score for suspected pediatric patients with Marfan syndrome. *Acta Paediatr*, 2013, 102, s. e84–89.
- Rathleff, M. – Skuldbol, S. – Rash, M., et al.: Care-seeking behaviour of adolescents with knee pain: a population-based study among 504 adolescents. *BMC Musculoskelet Disord*, 2013, 14, s. 225.
- Khubachandri, R. – Cimaz, R. – Cattalini, M.: Differential diagnosis 2: Non-inflammatory causes of musculoskeletal pain. In: *EULAR Textbook on pediatric rheumatology*. *BMJ*, 2018, s. 245–274.
- Muenzer, J.: The mucopolysaccharidoses: a variable heterogeneous group of disorders with variable pediatric presentations. *J Pediatr*, 2004, 144, s. S27–S34.
- Cimaz, R. – Coppa, G. V. – Koné-Paut, I., et al.: Koint contractures in the absence of inflammation may indicate mucopolysaccharidosis. *Pediatr Rheumatol Online J*, 2009, 7, s. 18.
- Aldenhoven, M. – Sakkars, R. J. – Bolenes, J., et al.: Musculoskeletal manifestations of lysosomal storage disorders. *Ann Rheum Dis*, 2009, 68, s. 1659–1665.
- Morishita, K. – Petty, R. E.: Musculoskeletal manifestations of mucopolysaccharidoses. *Rheumatology*, 2011, 50, s. v19–v25.
- Superti-Furga, A. – Bonafé, L. – Rimoin, D. L.: Molecular-pathogenetic classification of genetic disorders of the skeleton. *Am J Med Genet*, 2001, 106, s. 282–293.
- Garcia-Segarra, N. – Mittaz, L. – Campos-Xavier, A. B., et al.: The diagnostic challenge of progressive pseudorheumatoid dysplasia (PPRD): a review of clinical features, radiographic features, and WISP3 mutations in 63 affected individuals. *Am J Med Genet A*, 2012, 160C, s. 217–229.

# Inhibitory interleukinu 6 v léčbě revmatoidní artritidy

MUDr. Heřman Mann Klinika revmatologie 1. LF UK a Revmatologický ústav, Praha

- Kim, G. W. – Lee, N. R. – Pi, R. H., et al.: IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. *Arch Pharm Res*, 2015, 38, s. 575–584.
- Genovese, M. C. – McKay, J. D. – Nasonov, E. L., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum*, 2008, 58, s. 2968–2980.
- Emery, P. – Keystone, E. – Tony, H. P., et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologics: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis*, 2008, 67, s. 1516–1523.
- Kremer, J. M. – Blanco, R. – Brzoso, M., et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthr Rheumatol*, 2011, 63, s. 609–621.
- Jones, G. – Sebba, A. – Gu, J., et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis*, 2010, 69, s. 88–96.
- Gabay, C. – Emery, P. – van Vollenhoven, R., et al.: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*, 2013, 381, s. 1541–1550.
- Huizinga, T. W. – Fleischmann, R. M. – Jasson, M., et al.: Sarilumab, a fully human monoclonal antibody against IL-6R $\alpha$  in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis*, 2014, 73, s. 1626–1634.
- Genovese, M. C. – Fleischmann, R. – Kivitz, A. J., et al.: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol*, 2015, 67, s. 1424–1437.
- Strand, V. – Kosinski, M. – Chen, C. I., et al.: Sarilumab plus methotrexate improves patient – reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. *Arthritis Res Ther*, 2016, 18, s. 198.
- Fleischmann, R. – van Adelsberg, J. – Lin, Y., et al.: Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol*, 2017, 69, s. 277–290.
- Burmester, G. R. – Lin, Y. – Patel, R., et al.: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*, 2017, 76, s. 840–847.
- Takeuchi, T. – Thorne, C. – Karpouzias, G., et al.: Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. *Ann Rheum Dis*, 2017, 76, s. 2001–2008.
- Aletaha, D. – Bingham, C. O. 3<sup>rd</sup> – Tanaka, Y., et al.: Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind,

placebo-controlled, parallel-group, multinational, phase 3 study. *Lancet*, 2017, 389, s. 1206–1217.

14 Taylor, P. C. – Schiff, M. H. – Wang, Q., et al.: Efficacy and safety of

monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group,

multinational, 52-week, phase 3 study. *Ann Rheum Dis*, 2018, 77, s. 658–666.

## Současné postavení inhibitorů Janus kináz v terapii revmatoidní artritidy

MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha

- Smolen, J. S. – Aletaha, D. – Barton, A., et al.: Rheumatoid arthritis. *Nat Rev Dis Primers*, 2018, 4, s. 18001.
- Smolen, J. S. – Landewe, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- Schwartz, D. M. – Bonelli, M. – Gadina, M., et al.: Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol*, 2016, 12, s. 25–36.
- Schwartz, D. M. – Kanno, Y. – Villarino, A., et al.: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. *Nature Reviews Drug Discovery*, 2017, 16, s. 843–862.
- Abildtrup, M. – Kingsley, G. H. – Scott, D. L.: Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. *J Rheumatol*, 2015, 1, s. 760–770.
- Kivitz, A. J. – Gutierrez-Urena, S. R. – Pooley, J., et al.: Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. *Arthritis Rheum*, 2017, 69, s. 709–719.
- Genovese, M. C. – Greenwald, M. – Codding, C., et al.: Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. *Arthritis Rheum*, 2017, 69, s. 932–942.
- Kavanaugh, A. – Kremer, J. – Ponce, L., et al.: Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). *Ann Rheum Dis*, 2017, 76, s. 1009–1019.
- Westhovens, R. – Taylor, P. C. – Alten, R., et al.: Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). *Ann Rheum Dis*, 2017, 76, s. 998–1008.
- Kremer, J. M. – Emery, P. – Camp, H. S., et al.: A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. *Arthritis & Rheumatology*, 2016, 68, s. 2867–2877.
- Genovese, M. C. – Smolen, J. S. – Weinblatt, M. E., et al.: Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis & Rheum*, 2016, 68, s. 2857–2866.
- Fleischmann, R.: Tofacitinib in the treatment of active rheumatoid arthritis in adults. *Immunotherapy*, 2018, 10, s. 39–56.
- Lee, E. B. – Fleischmann, R. – Hall, S., et al.: Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*, 2014, 370, s. 2377–2386.
- van Vollenhoven, R. F. – Fleischmann, R. – Cohen, S., et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 508–519.
- Fleischmann, R. – Kremer, J. – Cush, J., et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.
- van der Heijde D. – Tanaka, Y. – Fleischmann, R., et al.: Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum*, 2013, 65, s. 559–570.
- Kremer, J. – Li, Z. G. – Hall, S., et al.: Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med*, 2013, 159, s. 253–261.
- Burmester, G. R. – Blanco, R. – Charles-Schoeman, C., et al.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet*, 2013, 381, s. 451–460.
- Fleischmann, R. – Mysler, E. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and
- adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–468.
- Fleischmann, R. – Schiff, M. – van der Heijde, D., et al.: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. *Arthritis Rheum*, 2017, 69, s. 506–517.
- Taylor, P. C. – Keystone, E. C. – van der Heijde, D., et al.: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
- Douglas, M. – van der Heijde, D. – Chen, Y. C., et al.: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Ann Rheum Dis*, 2017, 76, s. 88–95.
- Genovese, M. C. – Kremer, J. – Zamani, O., et al.: Baricitinib in patients with refractory rheumatoid arthritis. *N Engl J Med*, 2016, 374, s. 1243–1252.
- Winthrop, K. L.: The emerging safety profile of JAK inhibitors in rheumatic disease. *Nat Rev Rheumatol*, 2017, 13, s. 320.
- Winthrop, K. L. – Yamanaka, H. – Valdez, H., et al.: Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. *Arthritis Rheum*, 2014, 66, s. 2675–2684.
- Charles-Schoeman, C. – Wicker, P. – Gonzalez-Gay, M. A., et al.: Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. *Semin Arthritis Rheum*, 2016, 46, s. 261–271.
- Charles-Schoeman, C. – Fleischmann, R. – Davignon, J., et al.: Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. *Arthritis Rheum*, 2015, 67, s. 616–625.
- Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro farmakoterapii revmatoidní artritidy 2017. *Čes Revmatol*, 2017, 25, s. 8–24.

## Dlouhodobé klinické zkušenosti s tofacitinibem a jeho zařazení do léčby revmatoidní artritidy

MUDr. Zdeněk Fojtík, Ph.D. Revmatologická ambulance, Interní a hematologická klinika FN a LF MU, Brno

- Smolen, J. S. – Landewe, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- Singh, J. A. – Saag, K. G. – Bridges, S. L. Jr., et al.: 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*, 2016, 68, s. 1–26.
- Meyer, D. M. – Jossan, M. I. – Li, X., et al.: Antiinflammatory activity and neutrophil reduction mediated by the JAK1/JAK3 inhibitor, CP-690,550 in rat adjuvant-induced arthritis. *J Inflamm*, 2010, 7, s. 41.
- Ghoreschi, K. – Jesson, M. I. – Li, X., et al.: Modulation of innate and adaptive immuneresponses by tofacitinib (CP-690,550). *J Immunol*, 2011, 186, s. 4234–4243.
- O'Sullivan, L. A. – Liongue, C. – Lewis, R. S., et al.: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. *Mol Immunol*, 2007, 44, s. 2497–2506.
- Hodge, J. A. – Kawabata, T. T. – Krishnaswami, S., et al.: The mechanism of action of tofacitinib – an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. *Clin Exp Rheumatol*, 2016, 34, s. 318–328.
- Fleischmann, R. – Cutolo, M. – Genovese, M. C., et al.: Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an Inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum*, 2012, 64, s. 617–629.
- Fleischmann, R. – Kremer, J. M. – Cush, J., et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.
- Lee, E. B. – Fleischmann, R. – Hall, S., et al.: Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med*, 2014, 370, s. 2377–2386.
- Fleischmann, R. – Mysler, E. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 29, s. 457–468.
- Fleischmann, R. – Mease, P. J. – Schwartzman, S., et al.: Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. *Clin Rheumatol*, 2017, 36, s. 15–24.
- Van Vollenhoven, R. F. – Fleischmann, R. – Cohen, S., et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 508–519.
- Burmester, G. R. – Blanco, R. – Charles-Schoeman, C., et al.: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an Inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet*, 2013, 381, s. 451–460.
- Vieira, M. C. – Zwillich, S. H. – Jansen, J. P., et al.: Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. *Clin Ther*, 2016, 38, s. 2628–2641.
- Bird, P. – Bensen, W. – El-Zorkany, B. – Kaine, J., et al.: Tofacitinib 5 mg twice daily in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. A comprehensive review of phase 3 efficacy and safety. *J Clin Rheumatol*, 2018; DOI: 10.1097/RHU.0000000000000786.
- Kremer, J. – Li, Z. G. – Hall, S., et al.: Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med*, 2013, 159, s. 253–261.
- Cohen, S. B. – Tanaka, Y. – Mariette, X., et al.: Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Ann Rheum Dis*, 2017, 76, s. 1252–1262.
- Wollenhaupt, J. – Silverfield, J. – Lee, E. B., et al.: Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. *J Rheumatol*, 2014, 41, s. 837–852.
- Cohen, S. – Radominski, S. C. – Gomez-Reino, J. J., et al.: Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. *Arthritis Rheumatol*, 2014, 66, s. 2924–2937.
- Boyce, E. G. – Vyas, D. – Rogan, E. L., et al.: Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies. *Pac Rel Outcomes Measures*, 2016, 7, s. 1–12.
- Strand, V. – Ahadieh, S. – French, J., et al.: Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. *Arthritis Res Ther*, 2015, 17, s. 362, DOI 10.1186/s13075-015-0880-2.
- Fleischmann, R. – Wollenhaupt, J. – Takiya, L., et al.: Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. *RMD Open*, 2017, 3, e000491, doi:10.1136/rmdopen-2017-000491.
- Wollenhaupt, J. – Silverfield, J. – Lee, E. B., et al.: Tofacitinib, an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years [poster]. American College of Rheumatology Annual Scientific Meeting, San Diego, CA, USA, 11–16. 11. 2017, poster 522.
- Strand, V. – Kavanaugh, A. – Kivitz, A. J., et al.: Long-term radiographic and patient-reported outcomes in patients with rheumatoid arthritis treated with tofacitinib: ORAL Start and ORAL Scan post-hoc analyses. *Rheumatol Ther*, 2018, <https://doi.org/10.1007/s40744-018-0113-7>.
- Reed, G. W. – Gerber, R. A. – Shan, Y., et al.: Comparative effectiveness of TNFi and XELJANZ monotherapy in clinical practice: Results from the US CORRONA registry. Poster prezentován na European League Against Rheumatism, Londýn, UK, 8–11. 6. 2016.
- Kavanaugh, A. – Geier, J. – Bingham, C., et al.: Real-world results from a 5-year post-approval safety surveillance of tofacitinib (Xeljanz): Over 3-year results from an ongoing US-based rheumatoid arthritis registry. Poster prezentován na American College of Rheumatology Annual Scientific Meeting, Washington D.C., USA, 11–16. 11. 2016.



# Nový inhibitor interleukinu 6 sarilumab v terapii revmatoidní artritidy

MUDr. Hana Ciferská, Ph.D. | MUDr. Kateřina Zegzulková Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- Aletaha, D. – Neogi, T. – Silman, A. J., et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum*, 2010, 62, s. 2569–2581.
- Scott, D. L. – Wolfe, F. – Huizinga, T. W.: Rheumatoid arthritis. *Lancet*, 2010, 376, s. 1094–1108.
- Scott, D. L.: Biologics-based therapy for the treatment of rheumatoid arthritis. *Clin Pharmacol Ther*, 2012, 91, s. 30–43.
- Furst, D. E. – Emery, P.: Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. *Rheumatology*, 2014, 53, s. 1560–1569.
- Raimondo, M. G. – Biggioggero, M. – Crotti, C., et al.: Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. *Drug Des Devel Ther*, 2017, 24, s. 1593–1603.
- Choy, E.: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. *Rheumatology (Oxford)*, 2012, 51, s. 3–11.
- Dayer, J. M. – Choy, E.: Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. *Rheumatology (Oxford)*, 2010, 49, s. 15–24.
- Abdel Meguid, M. H. – Hamad, Y. H. – Swilam, R. S., et al.: Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage. *Rheumatol Int*, 2013, 33, s. 697–703.
- Dostupné z: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/004254/WC500230068.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004254/WC500230068.pdf), vyhledáno 25. 7. 2018.
- Lee, D. B. – Daskalakis, N. – Xu, C., et al.: Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. *Clin Pharmacokinet*, 2017, 56, s. 607–615.
- Huizinga, T. W. – Fleischmann, R. M. – Jasson, M., et al.: Sarilumab, a fully human monoclonal antibody against IL-6R $\alpha$  in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis*, 2014, 73, s. 1626–1634.
- Genovese, M. C. – Fleischmann, R. – Kivitz, A. J., et al.: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol*, 2015, 67, s. 1424–1437.
- van der Heijde, D. – van Adelsberg, J. – van Hoogstraten, H., et al.: Clinical and radiographic outcomes after 3 years of sarilumab in patients with rheumatoid arthritis [abstract]. *Arthritis Rheumatol*, 2016, 68, suppl. 10.
- Boyapati, A. – Mshid, J. – Fiore, S. – van Adelsberg, J., et al.: Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. *Arthritis Res Ther*, 2016, 18, s. 225.
- Fleischmann, R. M. – van Adelsberg, J. – Lin, Y., et al.: Sarilumab and non biologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol*, 2017, 69, s. 277–290.
- Burmester, G. R. – Lin, Y. – Patel, R., et al.: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*, 2017, 76, s. 840–847.
- Kivitz, A. – Baret-Cormel, L. – van Hoogstraten, H., et al.: Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. *Rheumatol Ther*, 2018, 5, s. 231–242.
- Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.
- Scott, D. L.: Biologics-based therapy for the treatment of rheumatoid arthritis. *Clin Pharmacol Ther*, 2012, 91, s. 30–43.

## Inhibitory Janus kináz v léčbě revmatoidní artritidy – současné možnosti a poznatky

doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie LF UK a FN Hradec Králové

- Seif, F. – Khoshmirsafa, M. – Azami, H., et al.: The role of JAK-STAT signalling pathway and its regulators in the fate of T helper cells. *Bio Med Central*, 2017, 15, s. 23.
- O'Shea, J. J. – Schwartz, D. M. – Villarino, A. V., et al.: The JAK-STAT pathway: Impact on human disease and therapeutic intervention. *Annu Rev Med*, 2015, 66, s. 311–328.
- Kremer, J. M. – Bloom, B. J. – Breedveld, F. C., et al.: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. *Arthritis Rheum*, 2009, 60, s. 1895–1905.
- Cohen, S. – Fleischmann, R.: Kinase inhibitors: a new approach to rheumatoid arthritis treatment. *Curr Opin Rheumatol*, 2010, 22, s. 330–335.
- Genovese, M. C. – Kremer, J. – Zamani, O., et al.: Baricitinib in patients with refractory rheumatoid arthritis. *N Engl J Med*, 2016, 374, s. 1243–1252.
- Fleischmann, R. – Schiff, M. – van der Heijde, D., et al.: Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. *Arthritis Rheum*, 2017, 69, s. 506–517.
- Kuriya, B. – Cohen, M. D. – Keystone, E.: Baricitinib in rheumatoid arthritis: evidence to-date and clinical potential. *Ther Adv Musculoskel Dis*, 2017, 9, s. 37–44.
- Cohen, S. B. – Tanaka, Y. – Mariette, X., et al.: Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Ann Rheum Dis*, 2017, 76, s. 1253–1262.
- Keystone, E. C. – Genovese, M. C. – Schlichting, D. E., et al.: Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. *J Rheumatol*, 2018, 45, s. 14–21.
- Scott, I. C. – Hider, S. L. – Scott, D. L.: Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: How real is the risk? *Drug Saf*, 2018, <https://doi.org/10.1007/s40264-018-0651-1>.
- van Vollenhoven, R. F. – Fleischmann, R. – Cohen, S., et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 508–519.
- Fleischmann, R. – Mysler, E. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–468.
- Bergrath, E. – Gerber, R. A. – Gruben, D., et al.: Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: Systematic literature review and network meta-analysis. *Int J Rheumatol*, 2017, doi: 10.1155/2017/8417249, Epub 9. 3. 2017.
- Vieira, M. C. – Zwillich, S. H. – Jansen, J. P., et al.: Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. *Clin Ther*, 2016, 38, s. 2628–2644.
- Mease, P. – Hall, S. – FitzGerald, O., et al.: Tofacitinib or adalimumab versus placebo for psoriatic arthritis. *N Engl J Med*, 2017, 377, s. 1537–1550.
- van der Heijde, D. – Deodhar, A. – Wei, J. C., et al.: Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo controlled, dose-ranging study. *Ann Rheum Dis*, 2017, 76, s. 1340–1347.
- Cheung, T. T. – McInnes, I. B.: Future therapeutic targets in rheumatoid arthritis? *Semin Immunopathol*, 2017, 39, s. 487–500.
- Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.

## Injekční roztok metotrexátu v předplněné injekční stříkačce – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Keininger, D. – Coteur, G.: Assessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ). *Health Qual. Life Outcomes*, 2011, 9, s. 2.
- Berteau, C. – Schwarzenbach, F. – Donazzolo, Y., et al.: Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. *Patient Prefer Adherence*, 2010, 4, s. 379–388.
- Lugaresi, A. – Durastanti, V. – Gasperini, C., et al.: Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. *Clin Neuropharmacol*, 2008, 31, s. 167–172.
- Cipriani, P. – Ruscitti, P. – Carubbi, F., et al.: Methotrexate: an old new drug in autoimmune disease. *Expert Rev Clin Immunol*, 2014, 10, s. 1519–1530.
- Cipriani, P. – Ruscitti, P. – Carubbi, F., et al.: Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. *Clin Ther*, 2014, 36, s. 427–435.
- Hudry, C. – Lebrun, A. – Moura, B., et al.: Evaluation of usability and acceptance of a new autoinjector intended for methotrexate subcutaneous self-administration in the management of rheumatoid arthritis. *Rheumatol Ther*, 2017, 4, s. 183–194.

## Leflunomid v léčbě revmatoidní artritidy

MUDr. Martin Klein, Ph.D. Revmatologický ústav, Praha

- Pavelka, K., et al.: *Farmakoterapie revmatických onemocnění*. Maxdorf, Praha, 2017.
- Leflunomid, souhrn údajů o přípravku (SPC); [www.sukl.cz](http://www.sukl.cz), 2017.
- Suchý, D. – Voříšek, J.: Postavení leflunomidu v léčbě aktivní revmatoidní artritidy. *Klinická farmakologie a farmacie*, 2014, 28, 2.
- Strand, V. – Cohen, S. – Schiff, M., et al.: Treatment of active rheumatoid arthritis with leflunomid compared with placebo and methotrexate. *Arch Intern Med*, 1999, 159, s. 2542–2550.
- Smolen, J. S. – Kalden, J. R. – Scott, D. L., et al.: Efficacy and safety of leflunomid compared with placebo and sulfasalazine in active rheumatoid arthritis: a double blind, randomized, multicenter study. *Lancet*, 1999, 353, s. 259–266.
- Behrens, F. – Koehm, M. – Burkhardt, H.: Update 2011: leflunomid in rheumatoid arthritis-strength and weaknesses. *Curr Opin Rheum*, 2011, 23, s. 282–287.
- Alfaro-Lara, R. – Espinosa-Ortega, H. F. – Arce-Salinas, C. A.: PRECIS study group, all physicians belong to Division of Internal Medicine. Hospital CentralS ur de Pemex. Systematic review and meta-analysis of the efficacy and safety of leflunomid and methotrexate in the treatment of rheumatoid arthritis. *Rheumatol Clin*, 31. 8. 2017.
- Smolen, J. S. – Landewé, R. – Bijlsma, J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*, 2017, 76, s. 960–977.

- 9 Tam, L. S. – Li, E. K. – Wong, C. K., et al.: Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. *Lupus*, 2004, 13, s. 601.
- 10 de Souza, R. C. – de Souza, F. H. C. – Miossi, R., et al.: Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. *Clin Exp Rheumatol*, 2017, 35, s. 1011–1013.

## Injekční versus perorální forma nízkodávkovaného metotrexátu

doc. MUDr. Karel Urbánek, Ph.D. Ústav farmakologie LF UP a FN, Olomouc

- 1 Svobodová, R.: Současné postavení metotrexátu v léčbě revmatoidní artritidy. *Prakt Lékař*, 2014, 10, s. 206–209.
- 2 Gabbani, T. – Deiana, S. – Lunardi, S., et al.: Safety profile of methotrexate in inflammatory bowel disease. *Expert Opin Drug Saf*, 2016, 15, s. 1427–1437.
- 3 Cipriani, P. – Ruscitti, P. – Carubbi, F., et al.: Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. *Clin Ther*, 2014, 36, s. 427–435.
- 4 Jay, R.: Methotrexate revisited: considerations for subcutaneous administration in RA. *Clin Rheumatol*, 2015, 34, s. 201–205.
- 5 Dervieux, T. – Furst, D. – Lein, D. O., et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. *Arthritis Rheum*, 2004, 50, s. 2766–2774.
- 6 Stamp, L. K. – Barclay, M. L. – O'Donnell, J. L., et al.: Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. *J Rheumatol*, 2011, 38, s. 2540–2547.
- 7 Řiháček, M. – Pilátová, K. – Štěrbá, J., et al.: Nové poznatky ve farmakologii metotrexátu – diagnostické možnosti a klinický význam. *Klin Onkol*, 2015, 28, s. 163–170.
- 8 Tornero, M. J. – Ballina, G. F. J. – Calvo, A. J., et al.: Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes. *Rheumatol Clin*, 2015, 11, s. 3–8.
- 9 Bello, A. E. – Perkins, E. L. – Jay, R., et al.: Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. *Open Access Rheumatol*, 2017, 9, s. 67–79.
- 10 Dalkilic, E. – Sahbazlar, M. – Gullulu, M., et al.: The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. *Mod Rheumatol*, 2013, 23, s. 525–528.
- 11 Schiff, M. H. – Jaffe, J. S. – Freundlich, B.: Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses  $\geq 15$  mg may be overcome with subcutaneous administration. *Ann Rheum Dis*, 2014, 73, s. 1549–1551.
- 12 Yazici, Y. – Bata, Y.: Parenteral methotrexate for the treatment of rheumatoid arthritis. *Bull Hosp Jt Dis*, 2013, 71, suppl. 1, s. 46–48.
- 13 Li, D. – Yang, Z. – Kang, P., et al.: Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. *Semin Arthritis Rheum*, 2016, 45, s. 656–662.
- 14 Yadlapati, S. – Eftimiou, P.: Inadequate response or intolerance to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics? *Rheumatol Int*, 2016, 36, s. 627–633.
- 15 Rohr, M. K. – Mikuls, T. R. – Cohen, S. B., et al.: Underuse of methotrexate in the treatment of rheumatoid arthritis: a national analysis of prescribing practices in the US. *Arthritis Care Res (Hoboken)*, 2017, 69, s. 794–800.

## Léčba osteoartrózy v praxi

MUDr. Marta Olejárová, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- 1 Löfvendahl, S. – Bizjajeva, S. – Ranstam, J., et al.: Indication for hip and knee replacement in Sweden. *J Eval Clin Pract*, 2011, 17, s. 251–260.
- 2 Bijlsma, J. W. – Berenbaum, F. – Lafeber, F. P.: Osteoarthritis: an update with relevance for clinical practice. *Lancet*, 2011, 377, s. 2115–2126.
- 3 Jordan, K. M. – Arden, N. K. – Doherty, M. – Bannwarth, B. – Bijlsma, J. W. J. – Pavelka, K., et al.: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). *Ann Rheum Dis*, 2004, 63, s. 1145–1155.
- 4 Zhang, W. – Doherty, M. – Arden, N. – Bannwarth, B. – Bijlsma, J. W. J. – Pavelka, K.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis*, 2004, 64, s. 669–681.
- 5 Zhang, W. – Doherty, M. – Leeb, B. F. – Alekseeva, L. – Arden, N. K. – Pavelka, K., et al.: EULAR evidence based recommendations for the management of hand osteoarthritis – report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Ann Rheum Dis*, 2007, 66, s. 377–388.
- 6 Fernandes, L. – Hagen, K. B. – Bijlsma, J. W. J. – Andreassen, O. – Christensen, P. – Pavelka, K., et al.: EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Ann Rheum Dis*, 2013, 72, s. 1125–1135.
- 7 Dostupné z: [https://www.eular.org/recommendations\\_management.cfm](https://www.eular.org/recommendations_management.cfm), vyhledáno 29. 8. 2018.
- 8 Zhang, W. – Moskowitz, R. W. – Nuki, G., et al.: OARSIS evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage*, 2008, 16, s. 137–162.
- 9 Zhang, W. – Nuki, G. – Moskowitz, R. W., et al.: OARSIS recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage*, 2010, 18, s. 476–499.
- 10 <https://www.oarsi.org/education/oarsi-guidelines>
- 11 Hochberg, M. C. – Altman, R. D. – April, K. T., et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)*, 2012, 64, s. 465–474.
- 12 Bruyère, O. – Cooper, C. – Pelletier, J. P., et al.: An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum*, 2014, 44, s. 253–263.
- 13 Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu osteoartrózy kolenních, kyčelních a ručních kloubů. *Čes Revmatol*, 2012, 20, s. 138–157.
- 14 Micca, J. L. – Ruff, D. – Ahl, J., et al.: Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials. *BMC Musculoskelet Disord*, 2013, 14, s. 137.

## Glukosamin sulfát v terapii osteoartrózy

MUDr. Monika Gregová, Ph.D. Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha

- 1 WHO: Musculoskeletal conditions. Fact sheet, únor 2018. Dostupné z: <http://www.who.int/mediacentre/factsheets/musculoskeletal/en/>, vyhledáno 31. 8. 2018.
- 2 Imboden, J. B. – Hellmann, D. B. – Stone, J. H.: *Current Diagnosis & Treatment: Rheumatology*. McGraw-Hill Medical, 2013, s. 327–331.
- 3 Heinemeier, K. M. – Schjerling, P. – Heinemeier, J., et al.: Radiocarbon dating reveals minimal kolagen turnover in both healthy and osteoarthritic human cartilage. *Sci Transl Med*, 2016, 8, s. 346ra90.
- 4 Pavelka, K. – Vencovský, J. – Horák, P. – Šenolt, L. – Mann, H. – Štěpán, J., et al.: *Revmatologie*. Maxdorf, 2012, s. 448–463.
- 5 Blagojevic, M. – Jinks, C. – Jeffery, A., et al.: Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. *Osteoarthritis Cartilage*, 2010, 18, s. 24.
- 6 Hammer, N. M. – Bieler, T. – Beyer, N., et al.: The impact of self-efficacy on physical activity maintenance in patients with hip osteoarthritis – a mixed methods study. *Disabil Rehabil*, 2016, 38, s. 1691.
- 7 Zhang, W. – Doherty, M. – Arden, N., et al.: EULAR recommendations: an evidence based medicine approach to the management of hip osteoarthritis. Report of task force of ESCISIT. *Ann Rheum Dis*, 2005, 64, s. 669–681.
- 8 McAlindon, T. E. – Bannuru, R. R. – Sullivan, M. C., et al.: OARSIS guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartil*, 2014, 22, s. 363–388.
- 9 da Costa, B. R. – Reichenbach, S. – Keller, N., et al.: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet*, 2017, 390, s. e21–e33.
- 10 Roberts, E. – Delgado Nunes, V. – Buckner, S., et al.: Paracetamol: not as safe as we thought? A systematic literature review of observational studies. *Ann Rheum Dis*, 2016, 75, s. 552.
- 11 Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu osteoartrózy kolenních, kyčelních a ručních kloubů. *Česká revmatologie*, 2012, 3, s. 138–157.
- 12 Bruyère, O. – Cooper, C. – Pelletier, J. P., et al.: An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum*, 2014, 44, s. 253–263.
- 13 Pavelka, K. – Vencovský, J. – Šenolt, L. – Horák, P. – Olejárová, M. – Tomčík, M. – Závada, J. – Štěpán, J., et al.: *Farmakoterapie revmatických onemocnění*. Maxdorf, 2017, 2, s. 255.
- 14 Persiani, S. – Rotini, R. – Trisolino, G., et al.: Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. *Osteoarthritis Cartil*, 2007, 15, s. 764–772.
- 15 Varghese, S. – Theorungsirikul, P. – Sahani, S., et al.: Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. *Osteoarthritis Cartil*, 2007, 15, s. 59–68.
- 16 Stoppoloni, D. – Politi, L. – Leopizzi, M., et al.: Effect of glucosamine and its peptidyl-derivative on the production of extracellular matrix components by human primary chondrocytes. *Osteoarthritis Cartil*, 2015, 23, s. 103–113.
- 17 Igarashi, M. – Sakamoto, K. – Nagaoka, I.: Effect of glucosamine on expression of type II collagen, matrix metalloproteinase and sirtuin genes in a human chondrocyte cell line. *Int J Molecul Med*, 2017, 39, s. 472–478.
- 18 Largo, R. – Alvarez-Soria, M. A. – Diez-Ortego, I., et al.: Glucosamine inhibits IL-1 beta induced NfκB activation in human osteoarthritic chondrocytes. *Osteoarthritis Cartil*, 2003, 11, s. 290–298.
- 19 Gouze, J. N. – Bianchi, A. – Becuwe, P., et al.: Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. *FEBS Lett*, 2002, 510, s. 166–170.
- 20 Chan, P. S. – Caron, J. P. – Rosa, G. J., et al.: Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. *Osteoarthritis Cartil*, 2005, 13, s. 387–394.
- 21 Taniguchi, S. – Ryu, J. – Seki, M., et al.: Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. *J Orthop Res*, 2012, 30, s. 673–678.
- 22 Pavelka, K. – Gatterova, J. – Olejárová, M., et al.: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. *Arch Intern Med*, 2002, 162, s. 2113–2123.
- 23 Pavelka, K. – Bruyere, O. – Rovati, L. C., et al.: Relief in mild-to-moderate pain is not confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials. *Osteoarthritis Cartil*, 2003, 11, s. 730–737.
- 24 Wandel, S. – Juni, P. – Tendal, B., et al.: Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *Br Med J*, 2010, 341, s. c4675.
- 25 Lee, Y. H. – Woo, J. H. – Choi, S. J., et al.: Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. *Rheumatol Int*, 2010, 30, s. 357–363.
- 26 Zhang, W. – Nuki, G. – Moskowitz, R. W., et al.: OARSIS recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of

- research published through January 2009. *Osteoarthr Cartil*, 2010, 18, s. 476–499.
- 27 **Fransen, M. – Agaliotis, M. – Nairn, L., et al.**: Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. *Ann Rheum Dis*, 2015, 74, s. 851–858.
- 28 **Runhaar, J. – Deroisy, R. – van Middelkoop, M., et al.**: The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the Prevention of knee Osteoarthritis in Overweight Females (PROOF) study. *Sem Arthritis Rheum*, 2016, 45, s. S42–S48.
- 29 **Towhead, T. E. – Maxwell, L. – Anastasiades, T. P., et al.**: Glucosamine therapy for treating osteoarthritis. *Cochrane Database Syst Rev*, 2005, 18, CD002946.
- 30 **Ogata, T. – Ideno, Y. – Akai, M., et al.**: Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. *Clin Rheumatol*, 2018, 37, s. 2479–2487.
- 31 **Clegg, D. – Reda, D. J. – Harris, C. L., et al.**: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med*, 2006, 354, s. 795.
- 32 **Zhu, X. – Sang, L. – Wu, D., et al.**: Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. *J Orthop Surg Res*, 2018, 13, s. 170.
- 33 **Hochberg, M. C. – Martel-Pelletier, J. – Monfort, J., et al.**: Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. *Ann Rheum Dis*, 2016, 75, s. 37–44.
- 34 **Persiani, S., et al.**: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. *Osteo Arthritis Cartilage*, 2005, 13, s. 1041–1049.
- 35 **Kucharz, E., et al.**: A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. *Curr Med Res Opin*, 2016, 32, s. 997–1004.
- 36 **Bruyère, O., et al.**: Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Aging Clin Exp Res*, 2018, 30, s. 111–117.
- 37 **Rovati, L. C., et al.**: Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmacology-Epidemiology of GonArthroSis (PEGASus) study. *Semin Arthritis Rheum*, 2016, 45, s. S34–S41.